Skip to Main Content

Author Details

Danny Y Song
Johns Hopkins University School of Medicine
1999
120
31
PMIDPaper TitleJournal TitlePublished Year
37812042TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.Prostate2024
37558543Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.Eur Urol Oncol2024
36316967The impact of salvage radiotherapy initiation at PSA⿿⿤⿿0.5⿿ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.Prostate2023
37173210Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.Eur Urol2023
37331778Histology Specific Molecular Biomarkers: Ushering in a New Era of Precision Radiation Oncology.Semin Radiat Oncol2023
37164128Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Ann Oncol2023
36717286A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.Eur Urol2023
36708787WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36179990External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.Int J Radiat Oncol Biol Phys2023
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
35050303Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.JAMA Oncol2022
35478055Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.Med Oncol2022
36001857Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.J Clin Oncol2022
34861998Mechanisms, Challenges, and Opportunities in Combined Radiation and Hormonal Therapies.Semin Radiat Oncol2022
35014708Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?Prostate2022
35013522Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.Prostate Cancer Prostatic Dis2022
32536574Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.Eur Urol Oncol2021
33722782Superior Postimplant Dosimetry Achieved Using Dynamic Intraoperative Dosimetry for Permanent Prostate Brachytherapy.Pract Radiat Oncol2021
34902034Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.JAMA Netw Open2021
34530868Employing a mobile health decision aid to improve decision-making for patients with advanced prostate cancer and their decision partners/proxies: the CHAMPION randomized controlled trial study design.Trials2021
33985797Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.Eur Urol2021
34196715Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.JAMA Netw Open2021
33451978Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.Clin Cancer Res2021
32798608Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2021
30992160Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.Eur Urol2020
31812829Improvements in Physician Clinical Workflow Measures After Implementation of a Dashboard Program.Pract Radiat Oncol2020
33090219Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.JAMA Oncol2020
33102622Automatic multi-organ segmentation in computed tomography images using hierarchical convolutional neural network.J Med Imaging (Bellingham)2020
32215577Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA Oncol2020
32487038A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).BMC Cancer2020
32341620CNN-based hierarchical coarse-to-fine segmentation of pelvic CT images for prostate cancer radiotherapy.Proc SPIE Int Soc Opt Eng2020
31454660Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer.Urology2020
30293905Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.Eur Urol2019
30191396Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.World J Urol2019
31215042Deformable registration of x ray and MRI for postimplant dosimetry in low dose rate prostate brachytherapy.Med Phys2019
31528661Deformable registration of PET/CT and ultrasound for disease-targeted focal prostate brachytherapy.J Med Imaging (Bellingham)2019
31196032A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).BMC Cancer2019
31419509Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.Int J Radiat Oncol Biol Phys2019
27811543Understanding Advanced Prostate Cancer Decision Making Utilizing an Interactive Decision Aid.Cancer Nurs2018
30217432Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.Brachytherapy2018
29976500Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.Int J Radiat Oncol Biol Phys2018
29551548Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.Urol Oncol2018
29520847Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.Prostate2018
29509865Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.JAMA2018
29153901Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.Pract Radiat Oncol2018
29174937Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.Brachytherapy2018
28045113Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.Prostate Cancer Prostatic Dis2017
28094250End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.Prostate Cancer Prostatic Dis2017
29060857Needle release mechanism enabling multiple insertions with an ultrasound-guided prostate brachytherapy robot.Annu Int Conf IEEE Eng Med Biol Soc2017
29168659Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity.Future Oncol2017
  • 1 - 50 of 120

Recommended Authors

Audrey Dang
Tulane University School of Medicine
Career Start Year 2018
Number of shared co-authors 25
Hilary P Bagshaw
Stanford University
Career Start Year 2014
Number of shared co-authors 27
Niluja Thiruthaneeswaran
The University of Sydney, Westmead Hospital
Career Start Year 2014
Number of shared co-authors 5
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 21
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 20
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 3
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 10
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 25
Mitchell Kamrava
Cedars Sinai Medical Center
Career Start Year 2005
Number of shared co-authors 15
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 18
Nima Aghdam
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 25
Minsong Cao
University of California Los Angeles
Career Start Year 2005
Number of shared co-authors 30
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 4
Andrew K Lee
Texas Center for Proton Therapy
Career Start Year 2001
Number of shared co-authors 2
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 45
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 32
Constantine A Mantz
University of Chicago
Career Start Year 1997
Number of shared co-authors 26
Eric Vigneault
Centre Hospitalier Universitaire de Quebec
Career Start Year 1997
Number of shared co-authors 13
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 26
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 11
Andrew Loblaw
Princess Margaret Hospital, University of Toronto
Career Start Year 1995
Number of shared co-authors 26
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 5
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 36
Jeff M Michalski
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 56
Seth A Rosenthal
Sutter Cancer Centers Radiation Oncology Services
Career Start Year 1987
Number of shared co-authors 44
Donald B Fuller
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Career Start Year 1986
Number of shared co-authors 18
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 25
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 64
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 64
Alan Pollack
University of Miami Miller School of Medicine
Career Start Year 1963
Number of shared co-authors 47

Collaborators

Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 59
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 41
Curtiland Deville
Johns Hopkins University
Co-authored papers 26
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 25
Todd McNutt
Johns Hopkins University School of Medicine
Co-authored papers 20
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 15
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 15
Ashley E Ross
Northwestern University
Co-authored papers 14
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 14
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 12
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 11
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 11
Ryan Phillips
Johns Hopkins University
Co-authored papers 10
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 10
Channing J Paller
Johns Hopkins University School of Medicine
Co-authored papers 10
Eric M Horwitz
Fox Chase Cancer Center
Co-authored papers 10
Amar U Kishan
University of California los angeles
Co-authored papers 9
Jay P Ciezki
Cleveland Clinic
Co-authored papers 8
Bradley J Stish
Mayo Clinic
Co-authored papers 8
Gregory S Merrick
Urologic Research Institute, Ohio University School of Medicine
Co-authored papers 8
Richard G Stock
Icahn School of Medicine at Mount Sinai
Co-authored papers 8
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 8
Eyad Abu-Isa
Ascension Providence Hospital
Co-authored papers 8
Wolfgang Lilleby
Oslo University Hospital
Co-authored papers 8
Jeffrey J Tosoian
Vanderbilt University Medical Center
Co-authored papers 8
Michael L Steinberg
University of California los angeles
Co-authored papers 8
David Jeffrey Demanes
University of California los angeles
Co-authored papers 8
Trude B Wedde
Oslo University Hospital
Co-authored papers 8
Chandana A Reddy
Cleveland Clinic
Co-authored papers 8
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 8
Release 1.2